ABUDUREXITI, M., ZHU, W., WANG, Y., WANG, J., XU, W., HUANG, Y., ZHU, Y., SHI, G., ZHANG, H., ZHU, Y., SHEN, Y., DAI, B., WAN, F., LIN, G. & YE, D. 2020. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. Prostate, 80, 950-961.
ARAO, T., UESHIMA, K., MATSUMOTO, K., NAGAI, T., KIMURA, H., HAGIWARA, S., SAKURAI, T., HAJI, S., KANAZAWA, A., HIDAKA, H., ISO, Y., KUBOTA, K., SHIMADA, M., UTSUNOMIYA, T., HIROOKA, M., HIASA, Y., TOYOKI, Y., HAKAMADA, K., YASUI, K., KUMADA, T., TOYODA, H., SATO, S., HISAI, H., KUZUYA, T., TSUCHIYA, K., IZUMI, N., ARII, S., NISHIO, K. & KUDO, M. 2013. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology, 57, 1407-15.
BEAULIEU, J. M., DEL'GUIDICE, T., SOTNIKOVA, T. D., LEMASSON, M. & GAINETDINOV, R. R. 2011. Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol Neurosci, 4, 38.
BRESLOW, D. K. & WEISSMAN, J. S. 2010. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol Cell, 40, 267-79.
BYRNE, F. L., OLZOMER, E. M., BRINK, R. & HOEHN, K. L. 2018. Knockout of glucose transporter GLUT6 has minimal effects on whole body metabolic physiology in mice. Am J Physiol Endocrinol Metab, 315, E286-e293.
BYRNE, F. L., OLZOMER, E. M., MARRIOTT, G. R., QUEK, L. E., KATEN, A., SU, J., NELSON, M. E., HART-SMITH, G., LARANCE, M., SEBESFI, V. F., CUFF, J., MARTYN, G. E., CHILDRESS, E., ALEXOPOULOS, S. J., POON, I. K., FAUX, M. C., BURGESS, A. W., REID, G., MCCARROLL, J. A., SANTOS, W. L., QUINLAN, K. G., TURNER, N., FAZAKERLEY, D. J., KUMAR, N. & HOEHN, K. L. 2020. Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress. Redox Biol, 28, 101374.
CAI, G., WANG, J., XIN, X., KE, Z. & LUO, J. 2007. Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol, 31, 657-62.
CASAMAYOR, A., MORRICE, N. A. & ALESSI, D. R. 1999. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J, 342 ( Pt 2), 287-92.
CERAMI, E., GAO, J., DOGRUSOZ, U., GROSS, B. E., SUMER, S. O., AKSOY, B. A., JACOBSEN, A., BYRNE, C. J., HEUER, M. L., LARSSON, E., ANTIPIN, Y., REVA, B., GOLDBERG, A. P., SANDER, C. & SCHULTZ, N. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov, 2, 401-4.
CONRARD, L. & TYTECA, D. 2019. Regulation of Membrane Calcium Transport Proteins by the Surrounding Lipid Environment. Biomolecules, 9.
DONEDA, D., NETTO, C. B., MOULIN, C. C. & SCHWARTZ, I. V. 2013. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond), 10, 34.
DUBOT, P., ASTUDILLO, L., THERVILLE, N., SABOURDY, F., STIRNEMANN, J., LEVADE, T. & ANDRIEU-ABADIE, N. 2020. Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers (Basel), 12.
ERTLE, J. M., HEIDER, D., WICHERT, M., KELLER, B., KUEPER, R., HILGARD, P., GERKEN, G. & SCHLAAK, J. F. 2013. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion, 87, 121-31.
GALICIA-MORENO, M., SILVA-GOMEZ, J. A., LUCANO-LANDEROS, S., SANTOS, A., MONROY-RAMIREZ, H. C. & ARMENDARIZ-BORUNDA, J. 2021. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Can J Gastroenterol Hepatol, 2021, 8837811.
GAO, J., AKSOY, B. A., DOGRUSOZ, U., DRESDNER, G., GROSS, B., SUMER, S. O., SUN, Y., JACOBSEN, A., SINHA, R., LARSSON, E., CERAMI, E., SANDER, C. & SCHULTZ, N. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 6, pl1.
GARRIDO, P., OSORIO, F. G., MORÁN, J., CABELLO, E., ALONSO, A., FREIJE, J. M. & GONZÁLEZ, C. 2015. Loss of GLUT4 induces metabolic reprogramming and impairs viability of breast cancer cells. J Cell Physiol, 230, 191-8.
GIUSSANI, P., TRINGALI, C., RIBONI, L., VIANI, P. & VENERANDO, B. 2014. Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int J Mol Sci, 15, 4356-92.
HAN, F., LI, C. F., CAI, Z., ZHANG, X., JIN, G., ZHANG, W. N., XU, C., WANG, C. Y., MORROW, J., ZHANG, S., XU, D., WANG, G. & LIN, H. K. 2018. The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun, 9, 4728.
HOPKINS, T. A., DYCK, J. R. & LOPASCHUK, G. D. 2003. AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart. Biochem Soc Trans, 31, 207-12.
ISHIBASHI, Y. & HIRABAYASHI, Y. 2015. AMP-activated Protein Kinase Suppresses Biosynthesis of Glucosylceramide by Reducing Intracellular Sugar Nucleotides. J Biol Chem, 290, 18245-60.
JENNEMANN, R., FEDERICO, G., MATHOW, D., RABIONET, M., RAMPOLDI, F., POPOVIC, Z. V., VOLZ, M., HIELSCHER, T., SANDHOFF, R. & GRÖNE, H. J. 2017. Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis. Oncotarget, 8, 109201-109216.
KIM, J. A. 2020. Peroxisome Metabolism in Cancer. Cells, 9.
LACHKAR, F., FERRÉ, P., FOUFELLE, F. & PAPAIOANNOU, A. 2021. Dihydroceramides: their emerging physiological roles and functions in cancer and metabolic diseases. Am J Physiol Endocrinol Metab, 320, E122-e130.
LI, J. F., ZHENG, S. J., WANG, L. L., LIU, S., REN, F., CHEN, Y., BAI, L., LIU, M. & DUAN, Z. P. 2017. Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl‑2/Bax pathway. Mol Med Rep, 16, 7355-7360.
LIANG, H. & WARD, W. F. 2006. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ, 30, 145-51.
LIVINGSTONE, C. 2013. IGF2 and cancer. Endocr Relat Cancer, 20, R321-39.
LLOVET, J. M., RICCI, S., MAZZAFERRO, V., HILGARD, P., GANE, E., BLANC, J. F., DE OLIVEIRA, A. C., SANTORO, A., RAOUL, J. L., FORNER, A., SCHWARTZ, M., PORTA, C., ZEUZEM, S., BOLONDI, L., GRETEN, T. F., GALLE, P. R., SEITZ, J. F., BORBATH, I., HÄUSSINGER, D., GIANNARIS, T., SHAN, M., MOSCOVICI, M., VOLIOTIS, D. & BRUIX, J. 2008. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90.
LONG, J., LANG, Z. W., WANG, H. G., WANG, T. L., WANG, B. E. & LIU, S. Q. 2010. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas. Hepatobiliary Pancreat Dis Int, 9, 296-305.
NELSON, M. E., LAHIRI, S., CHOW, J. D., BYRNE, F. L., HARGETT, S. R., BREEN, D. S., OLZOMER, E. M., WU, L. E., COONEY, G. J., TURNER, N., JAMES, D. E., SLACK-DAVIS, J. K., LACKNER, C., CALDWELL, S. H. & HOEHN, K. L. 2017. Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival. Nat Commun, 8, 14689.
PARK, W. J., PARK, J. W., MERRILL, A. H., STORCH, J., PEWZNER-JUNG, Y. & FUTERMAN, A. H. 2014. Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length. Biochim Biophys Acta, 1841, 1754-66.
PERERA, S., KELLY, D. & O'KANE, G. M. 2020. Non-Immunotherapy Options for the First-Line Management of Hepatocellular Carcinoma: Exploring the Evolving Role of Sorafenib and Lenvatinib in Advanced Disease. Curr Oncol, 27, 165-172.
REGENBOOG, M., VAN DUSSEN, L., VERHEIJ, J., WEINREB, N. J., SANTOSA, D., VOM DAHL, S., HÄUSSINGER, D., MÜLLER, M. N., CANBAY, A., RIGOLDI, M., PIPERNO, A., DINUR, T., ZIMRAN, A., MISTRY, P. K., SALAH, K. Y., BELMATOUG, N., KUTER, D. J. & HOLLAK, C. E. M. 2018. Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis, 41, 819-827.
SANTIAGO-SÁNCHEZ, G. S., PITA-GRISANTI, V., QUIÑONES-DÍAZ, B., GUMPPER, K., CRUZ-MONSERRATE, Z. & VIVAS-MEJÍA, P. E. 2020. Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer. Int J Mol Sci, 21.
SCHÖMEL, N., GEISSLINGER, G. & WEGNER, M. S. 2020a. Influence of glycosphingolipids on cancer cell energy metabolism. Prog Lipid Res, 79, 101050.
SCHÖMEL, N., GRUBER, L., ALEXOPOULOS, S. J., TRAUTMANN, S., OLZOMER, E. M., BYRNE, F. L., HOEHN, K. L., GURKE, R., THOMAS, D., FERREIRÓS, N., GEISSLINGER, G. & WEGNER, M. S. 2020b. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells. Sci Rep, 10, 8182.
SCHÖMEL, N., HANCOCK, S. E., GRUBER, L., OLZOMER, E. M., BYRNE, F. L., SHAH, D., HOEHN, K. L., TURNER, N., GRÖSCH, S., GEISSLINGER, G. & WEGNER, M. S. 2019. UGCG influences glutamine metabolism of breast cancer cells. Sci Rep, 9, 15665.
SHI, L., AN, S., LIU, Y., LIU, J. & WANG, F. 2020. PCK1 Regulates Glycolysis and Tumor Progression in Clear Cell Renal Cell Carcinoma Through LDHA. Onco Targets Ther, 13, 2613-2627.
SIDDIQUE, M. M., LI, Y., WANG, L., CHING, J., MAL, M., ILKAYEVA, O., WU, Y. J., BAY, B. H. & SUMMERS, S. A. 2013. Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling. Mol Cell Biol, 33, 2353-69.
STEFANOVIC, M., TUTUSAUS, A., MARTINEZ-NIETO, G. A., BÁRCENA, C., DE GREGORIO, E., MOUTINHO, C., BARBERO-CAMPS, E., VILLANUEVA, A., COLELL, A., MARÍ, M., GARCÍA-RUIZ, C., FERNANDEZ-CHECA, J. C. & MORALES, A. 2016. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma. Oncotarget, 7, 8253-67.
TENEN, D. G., CHAI, L. & TAN, J. L. 2021. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf), 9, 1-13.
THOMAS, M. B., JAFFE, D., CHOTI, M. M., BELGHITI, J., CURLEY, S., FONG, Y., GORES, G., KERLAN, R., MERLE, P., O'NEIL, B., POON, R., SCHWARTZ, L., TEPPER, J., YAO, F., HALLER, D., MOONEY, M. & VENOOK, A. 2010. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol, 28, 3994-4005.
WANG, J. & LI, Y. 2019. CD36 tango in cancer: signaling pathways and functions. Theranostics, 9, 4893-4908.
WANG, N., WANG, S., LI, M. Y., HU, B. G., LIU, L. P., YANG, S. L., YANG, S., GONG, Z., LAI, P. B. S. & CHEN, G. G. 2018. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol, 10, 1758835918816287.
WEGNER, M. S., GRUBER, L., MATTJUS, P., GEISSLINGER, G. & GRÖSCH, S. 2018a. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1). BMC Cancer, 18, 153.
WEGNER, M. S., SCHÖMEL, N., GRUBER, L., ÖRTEL, S. B., KJELLBERG, M. A., MATTJUS, P., KURZ, J., TRAUTMANN, S., PENG, B., WEGNER, M., KAULICH, M., AHRENDS, R., GEISSLINGER, G. & GRÖSCH, S. 2018b. UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells. Cell Mol Life Sci, 75, 3393-3410.
WILLIAMS, M. R., ARTHUR, J. S., BALENDRAN, A., VAN DER KAAY, J., POLI, V., COHEN, P. & ALESSI, D. R. 2000. The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol, 10, 439-48.
WU, S., DU, R., GAO, C., KANG, J., WEN, J. & SUN, T. 2018. The role of XBP1s in the metastasis and prognosis of hepatocellular carcinoma. Biochem Biophys Res Commun, 500, 530-537.
XU, L. & ASH, J. D. 2016. The Role of AMPK Pathway in Neuroprotection. Adv Exp Med Biol, 854, 425-30.
YANG, C., LU, W., LIN, T., YOU, P., YE, M., HUANG, Y., JIANG, X., WANG, C., WANG, F., LEE, M. H., YEUNG, S. C., JOHNSON, R. L., WEI, C., TSAI, R. Y., FRAZIER, M. L., MCKEEHAN, W. L. & LUO, Y. 2013. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol, 13, 67.
YANG, J. & MOSES, M. A. 2009. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle, 8, 2347-52.
YILDIZ, G. 2018. Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells. Oncol Lett, 16, 113-122.
ZOU, Z., TAO, T., LI, H. & ZHU, X. 2020. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci, 10, 31.